Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Inova Diagnostics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is concentrated under 1 distinct examiner and 1 distinct art unit. The busiest examiner for this portfolio is MACFARLANE, STACEY NEE. This specific examiner is responsible for 1 pending office action, which represents the entirety of the company's current pending workload. This 1 pending action is the sole focus for the busiest examiner.
For a practitioner, this concentration suggests a focused prosecution strategy where all current outcomes depend on the review of MACFARLANE, STACEY NEE. Such a structure may allow for direct communication during the patent acquisition process. The presence of 1 distinct examiner indicates that the company is not currently juggling several conflicting examiner styles or requirements across its portfolio.
Because the work is limited to the assigned art unit, the legal team can specialize their approach to the specific standards and precedents of that unit. This singular focus in the Biotechnology & Pharmaceuticals area simplifies the management of deadlines and examiner interviews. The data shows a portfolio that is currently narrow in its examiner and art unit engagement, which may result in a more predictable prosecution timeline compared to portfolios spread across many units. This 1 distinct art unit defines the current technical boundary of the company's pending claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACFARLANE, STACEY NEE | 1 | 53.5% | +39.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17961412 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND ASSESSING RHEUMATOID ARTHRITIS USING PROTEIN-ARGININE DEIMINASE 1 (PAD1) AUTOANTIGENS | MACFARLANE, STACEY NEE | 12d |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17961412 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND ASSESSING RHEUMATOID ARTHRITIS USING PROTEIN-ARGININE DEIMINASE 1 (PAD1) AUTOANTIGENS | MACFARLANE, STACEY NEE | 1675 | §103§112DP | Non-Final OA | 12d | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial